logo
  

BioSante's LibiGel Fails To Meet Endpoints In Female Sexual Disorder Studies

BioSante Pharmaceuticals, Inc. (BPAX) Wednesday said LibiGel did not meet the co-primary or secondary endpoints in two pivotal Phase III efficacy trials in the treatment of hypoactive sexual desire disorder in postmenopausal women. The trials were conducted according to an FDA-agreed special protocol assessment agreement.

LibiGel is in development for the treatment of female sexual dysfunction, specifically, hypoactive sexual desire disorder or HSDD in postmenopausal women, for which there is no FDA-approved product.

The co-primary endpoints of both LibiGel efficacy trials were the change in the total number of days with a satisfying sexual event from baseline, and the change in mean sexual desire from baseline. The secondary endpoint for both trials was the change in sexual distress from baseline.

Subjects in the first trial, called BLOOM-1, who were treated with LibiGel showed an increase of 1.47 days with a satisfying sexual event compared to baseline, while those receiving placebo gel showed an increase of 1.26 days with a satisfying sexual event compared to baseline.

Subjects in BLOOM-2 who were treated with LibiGel showed an increase of 1.0 day with a satisfying sexual event compared to baseline, while those receiving placebo gel showed an increase of 1.28 days with a satisfying sexual event compared to baseline.

Although there were no statistical differences in the endpoints, BioSante said all results were in the appropriate directions. The LibiGel groups in both trials showed an increase in free testosterone levels compared to baseline and placebo.

The trials demonstrated that LibiGel was generally well tolerated with a safety profile that appeared to be comparable to placebo.

The two completed Phase III efficacy trials were randomized, double-blind, placebo-controlled trials which enrolled 597 and 575 surgically menopausal women, respectively, for six-months of therapy.

BioSante continues to conduct the Phase III LibiGel safety study, a cardiovascular events and breast cancer study that has completed enrollment of 3,656 women and has accrued over 5,100 women-years of exposure, to date. The study is designed for a total of five years; however, BioSante could use the safety study data as part of a New Drug Application (NDA) submission after the last subject enrolled has completed 12 months of exposure to LibiGel or placebo.

Stephen Simes, Lincolnshire, Illinois-based BioSante's president & CEO, said," We will continue to analyze the efficacy trial data fully and determine plans for our next steps in the LibiGel development plan, and provide an update at a later time."

BPAX closed Wednesday's regular trade at $2.12, down $0.40 or 15.87%, on the Nasdaq. In the after-hours, the stock gained $0.01 or 0.47%. Over the past year, the stock traded in a range of $1.47 - $4.02.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Asweets Global Inc. is recalling about 2,000 units of Wonder & Wise Activity Tables for potential risk of choking hazard to young children, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the screws of the tables can become loose and/or detach from the xylophone component of the activity tables to pose a choking hazard to young children. Chinese e-commerce giant Alibaba Group Holdings Ltd. (BABA) reported Thursday a net loss for the fourth quarter that sharply widened from last year, despite 9 percent growth in revenues, hurt by a decreases in the market prices of our equity investments in publicly-traded companies. Omni-channel fashion retailer Macy's, Inc. (M) reported Thursday a first-quarter net income of $286 million or $0.98 per share, sharply higher than $103 million or $0.32 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $315 million or $1.08 per share, compared...
Follow RTT